Successful implementation of X‐ray‐activated photodynamic therapy (X‐PDT) is challenging because most photosensitizers (PSs) absorb light in the blue region, but few nanoscintillators produce efficient blue scintillation. Here, efficient blue‐emitting SrF 2 :Eu scintillating nanoparticles (ScNPs) are developed. The optimized synthesis conditions result in cubic nanoparticles with ≈32 nm diameter and blue emission at 416 nm. Coating them with the meso‐tetra( n ‐methyl‐4‐pyridyl) porphyrin (TMPyP) in a core–shell structure (SrF@TMPyP) results in maximum singlet oxygen ( 1 O 2 ) generation upon X‐ray irradiation for nanoparticles with 6TMPyP depositions (SrF@6TMPyP). The 1 O 2 generation is directly proportional to the dose, does not vary in the low‐energy X‐ray range (48–160 kVp), but is 21% higher when irradiated with low‐energy X‐rays than irradiations with higher energy gamma rays. In the clonogenic assay, cancer cells treated with SrF@6TMPyP and exposed to X‐rays present a significantly reduced survival fraction compared to the controls. The SrF 2 :Eu ScNPs and their conjugates stand out as tunable nanoplatforms for X‐PDT due to the efficient blue emission from the SrF 2 :Eu cores; the ability to adjust the scintillation emission in terms of color and intensity by controlling the nanoparticle size; the efficient 1 O 2 production when conjugated to a PS and the efficacy of killing cancer cells.
No takes yet. Share an insight, caveat, or question.
Marques et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: